

Title (en)
METHODS OF TREATING SPLENOMEGALY

Title (de)
VERFAHREN ZUR BEHANDLUNG VON SPLENOMEGALIE

Title (fr)
MÉTHODES DE TRAITEMENT D'UNE SPLÉNOMÉGALIE

Publication
EP 3980069 A4 20220817 (EN)

Application
EP 21738476 A 20210108

Priority
• US 202062958632 P 20200108
• US 2021012696 W 20210108

Abstract (en)
[origin: WO2021142257A1] Therapeutic methods and pharmaceutical compositions for treating splenomegaly in a human subject are described. In certain embodiments, the invention includes therapeutic methods of treating splenomegaly using a BTK inhibitor.

IPC 8 full level
A61K 31/4985 (2006.01); **A61K 31/519** (2006.01); **A61P 29/00** (2006.01)

CPC (source: EP IL KR)
A61K 31/4985 (2013.01 - EP IL KR); **A61K 31/519** (2013.01 - EP IL KR); **A61P 29/00** (2018.01 - EP IL); **A61P 35/02** (2018.01 - KR)

Citation (search report)
• [T] WO 2021097213 A1 20210520 - QUOGUE IP HOLDINGS LLC [US]
• [Y] WO 2016024230 A1 20160218 - ACERTA PHARMA BV [NL]
• [A] WO 2015057992 A1 20150423 - IZUMI RAQUEL [US], et al
• [A] US 2016122365 A1 20160505 - CASTRO ALFREDO C [US], et al
• [Y] WO 2019243223 A1 20191226 - MERCK PATENT GMBH [DE]
• [Y] MICHAEL L. WANG ET AL: "Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, no. 6, 8 August 2013 (2013-08-08), US, pages 507 - 516, XP055484912, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1306220
• [A] ON BEHALF OF THE INVESTIGATORS OF THE ITALIAN REGISTRY OF MYELOFIBROSIS WITH MYELOID METAPLASIA AND THE MYELOPROLIFERATIVE DISORDE: "The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia", BLOOD CELLS, MOLECULES & DISEASES, LAJOLLA, US, vol. 38, no. 3, 4 April 2007 (2007-04-04), pages 280 - 286, XP022014560, ISSN: 1079-9796, DOI: 10.1016/J.BCMD.2007.01.003
• [I] JAMIE L DARGART ET AL: "Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 95, no. 1, 7 May 2012 (2012-05-07), pages 49 - 56, XP028491144, ISSN: 0166-3542, [retrieved on 20120516], DOI: 10.1016/J.ANTIVIRAL.2012.05.003
• [Y] ASHANGARI CHANDRALEKHA ET AL: "Hairy Cell Leukemia Variant", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 5562, XP086591091, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-110192
• See also references of WO 2021142257A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2021142257 A1 20210715; AU 2021205484 A1 20220818; BR 112022013646 A2 20221004; CA 3164063 A1 20210715; CN 114423457 A 20220429; CO 2022010592 A2 20221031; CR 20220374 A 20230125; EP 3980069 A1 20220413; EP 3980069 A4 20220817; EP 4000624 A1 20220525; IL 294582 A 20220901; JO P20220168 A1 20230130; JP 2023509968 A 20230310; KR 20220130151 A 20220926; MA 57226 A1 20230228; MA 57226 B1 20230628; MA 63848 A1 20240430; MX 2022008490 A 20221013

DOCDB simple family (application)
US 2021012696 W 20210108; AU 2021205484 A 20210108; BR 112022013646 A 20210108; CA 3164063 A 20210108; CN 202180004918 A 20210108; CO 2022010592 A 20220728; CR 20220374 A 20210108; EP 21738476 A 20210108; EP 22150344 A 20210108; IL 29458222 A 20220707; JO P20220168 A 20210108; JP 2022542216 A 20210108; KR 20227027305 A 20210108; MA 57226 A 20210108; MA 63848 A 20210108; MX 2022008490 A 20210108